ClinicalTrials.gg
CompletedNCT04313712Updated Oct 27, 2026

Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure

An observational study in Blast or Combat Exposure and Head Injury Trauma, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Stanford University · Observational

How we know

Updated Oct 27, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Craniocerebral Trauma with a site in United States — 12 open to participants now, 17 under way, none of them phase 3. Craniocerebral Trauma · United States.

Enrollment
30th of 33
30 · median 192
Started
2021
with 7 others
Observational
33 of 95
3 open now
Registered
69th of 95
by date

Among the 95 studies in Craniocerebral Trauma with a site in United States, this one is the 30th largest by enrollment of the 33 observational ones that give a count, is one of 8 that started in 2021, is one of 33 observational ones, and was the 69th registered.

Craniocerebral Trauma

253 studies on the registry are indexed under Craniocerebral Trauma; 45 are open to participants now.

Browse Craniocerebral Trauma studies →

Open to participants now

12 of the 95 studies in Craniocerebral Trauma with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Craniocerebral Trauma studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Craniocerebral Trauma with a site in United States, or all of them as a file.
02

Study summary

A Pre-post Study Evaluating the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans with Sequelae of Repeated Blast Exposure.

Read the detailed description

Traumatic brain injury (TBI) is a leading cause of disability worldwide and is particularly common among combat veterans. Deleterious sequelae can include functional impairments and comorbid psychiatric syndromes such as posttraumatic stress disorder (PTSD), depression, and anxiety. Special Operations Forces Veterans (SOV) may be at an elevated risk for these complications, leading some to seek treatment alternatives like the oneirogen ibogaine despite limited evidence of safety or efficacy.

We will assess the safety profile of the compound by assessing unexpected or serious adverse events.

The primary outcome will be change in the World Health Organization Disability Assessment Schedule 2.0 (WHODAS) from baseline to post-treatment, with change from baseline to the one-month follow-up a secondary outcome.

03

Conditions studied

  • Blast or Combat Exposure
  • Head Injury Trauma

Browse trials for

Keywords

  • blast exposure
  • combat exposure
  • head trauma
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Veterans with a history of head trauma, combat or blast exposure that have arranged for ibogaine-magnesium therapy in other countries.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female veteran, 18 to 70 years of age, inclusive, at screen.
  2. Able to read, understand, and provide written, dated prior to screening. Participants will be deemed likely to comply with the study protocol and communicate with study personnel about adverse events and other information.
  3. Has a history of head trauma, combat or blast exposure.
  4. Scheduled themselves for ibogaine-magnesium therapy at Nouvelle Vie in Mexico.
  5. Participants must be willing and able to travel to Stanford University before and after ibogaine-magnesium therapy.
  6. Capable of getting an MRI scan.
  7. Willing to be video recorded during the consenting process. (to be stored on a secure server, no PHI associated with video recordings)
  8. between 17-35kg/m2.
  9. If female, a status of non- or use of an acceptable form of per the following specific criteria:

    1. Non-childbearing potential (e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized (status post hysterectomy, bilateral tubal ligation), or is with her last menses at least one year prior to screening); or
    2. Childbearing potential, and meets the following criteria:

    i. Childbearing potential, including women using any form of hormonal birth control, on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent.

    ii. Negative urinary pregnancy test at screening, confirmed by a negative urinary pregnancy test at randomization prior to receiving study treatment.

    iii. Willing and able to continuously use one of the following methods of birth control during the course of the study, defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. The form of birth control will be documented at screening and baseline.

  10. Participants must be US citizens.

Exclusion criteria

Exclusion Criteria:

  1. Female of who is not willing to use one of the specified forms of during the study.
  2. Female that is pregnant or breastfeeding.
  3. Claustrophobic.
  4. History of a neurological disorder (i.e. Parkinson's, epilepsy, dementia, etc.) excluding sequelae of traumatic injury.
  5. In the judgment of the investigator, the subject is at significant risk for suicidal behavior during the course of their participation in the study.
  6. History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms.
  7. Has a abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results.
  8. Participation in any clinical trial with an drug or device within the past month or concurrent to study participation.
  9. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
  10. Any history of cardiovascular problems.
  11. Any history of liver or kidney problems.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants

    All study participants will be observed before and after they receive ibogaine-magnesium therapy.

    Drug: ibogaine with magnesium treatment

Interventions

  • Drugibogaine with magnesium treatment

    Participants will receive magnesium sulfate intravenously and ibogaine orally.

06

What researchers measure

Primary outcomes

  1. Change in score on the WHODAS 2.0

    The WHODAS 2.0 is a generic assessment of disability across six domains of functioning including cognition, mobility, self-care, interpersonal relationships, life activities, and community activities. The higher the score, the greater the level of self-reported disability in functioning. Scores from baseline will be compared to scores at the immediate post-treatment.

    Time frame: Baseline to immediate post visit.

Secondary outcomes

  1. Change in score on the WHODAS 2.0

    The WHODAS 2.0 is a generic assessment of disability across six domains of functioning including cognition, mobility, self-care, interpersonal relationships, life activities, and community activities. The higher the score, the greater the level of self-reported disability in functioning. Scores from baseline will be compared to scores at 1-month post-visit.

    Time frame: Baseline to 1-month post visit.

07

Study locations

1 site
  • Stanford University School of Medicine
    Stanford, California 94305, United States
08

References and documents

Publications

  • Cherian KN, Keynan JN, Anker L, Faerman A, Brown RE, Shamma A, Keynan O, Coetzee JP, Batail JM, Phillips A, Bassano NJ, Sahlem GL, Inzunza J, Millar T, Dickinson J, Rolle CE, Keller J, Adamson M, Kratter IH, Williams NR. Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nat Med. 2024 Feb;30(2):373-381. doi: 10.1038/s41591-023-02705-w. Epub 2024 Jan 5. PubMed 38182784 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Sep 2023, 21 months.

Of 43 non-industry observational studies under Craniocerebral Trauma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 21 months is below that.

Counting every sponsor, half of 43 studies reached it within 32 months; a quarter within 15 and three quarters within 49.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Feb 2025 → Sep 2023 and completion Feb 2025 → Sep 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
Mar 18, 2020
StartActual
Nov 15, 2021
Primary completionActual
Sep 13, 2023was Feb 2025
CompletionActual
Sep 13, 2023was Feb 2025
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 27, 2026
Primary completion
Feb 2025→Sep 13, 2023 (actual)
Oct 27, 2026
Study completion
Feb 2025→Sep 13, 2023 (actual)
Oct 27, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38182784 ↗
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Active, not recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38182784 ↗
    Primary completion Feb 2025→Sep 13, 2023 (now actual)
    Study completion Feb 2025→Sep 13, 2023 (now actual)
    + 4 other changes: verification date, responsible party, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04313712
Responsible party
Cammie Ellen Rolle (Clinical Associate Professor, Stanford University, Stanford University) — Principal investigator
First posted
Mar 18, 2020
Start date
Nov 15, 2021
Primary completion
Sep 13, 2023
Completion
Sep 13, 2023
Last update
Oct 27, 2026

Study contacts

Cammie Rolle, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion